DSS, Inc. (DSS) 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024. DSS, Inc. operates five distinct business segments: Product Packaging (Premier Packaging), Biotechnology (Impact BioMedical), Commercial Lending (American Pacific Financial), Securities and Investment Management (including REITs), and Direct Marketing. The company is a Non-Accelerated Filer and Smaller Reporting Company. In 2024, the company completed the IPO of its subsidiary, Impact BioMedical, Inc. (IBO), and appointed Jason Grady as Interim CEO.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $19.1 million | $25.9 million |
| Net Loss (Attributable to Common Stockholders) | $(46.9) million | $(60.6) million |
| Operating Loss | $(42.6) million | $(50.8) million |
| Cash and Cash Equivalents (Year End) | $11.4 million | $6.6 million |
| Total Assets | $106.5 million | $153.2 million |
| Total Liabilities | $73.7 million | $69.9 million |
| Stockholders' Equity | $32.7 million | $83.2 million |
Note: The company reported a significant reduction in net loss year-over-year, primarily driven by a decrease in impairment charges compared to 2023, despite a 26% decline in revenue.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 26% to $19.1 million. Printed products revenue fell 13% due to order timing shifts and customer reductions. Direct Marketing revenue dropped 100% as the company transitioned from a sales force model to a licensing model. Securities revenue declined 48% due to commission reductions.
- Impairment Charges: The company recorded a $25.1 million goodwill impairment related to Impact BioMedical and a $7.3 million impairment of real estate assets. This compares to $31.0 million in goodwill impairment and $7.4 million in intangible asset impairment in 2023.
- Debt and Defaults: Significant debt obligations related to the American Medical REIT (AMRE) segment are in default. Specifically, the LifeCare Agreement ($46.1 million) and Pinnacle Loan ($3.0 million) are past due. These assets are classified as "held for sale."
- Segment Performance: The Product Packaging segment generated a gross profit of $0.9 million, while the Biotechnology and Securities segments reported operating losses of $29.0 million and $7.5 million, respectively.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management is focused on cost reduction (targeting 15-20% reduction), operational efficiency, and expanding high-impact business lines like Premier Packaging. The company aims to monetize its biotechnology portfolio through licensing and the recently completed IBO IPO. The company believes it has sufficient cash ($11.4 million) and marketable securities ($9.2 million) to fund operations for the next 12 months, alleviating substantial doubt about its ability to continue as a going concern.
Risks and Contingencies:
- Debt Default: The company faces immediate liquidity pressure due to defaulted loans totaling over $49 million related to its REIT assets. Failure to negotiate extensions or sell these assets could lead to foreclosure.
- Customer Concentration: Two customers accounted for 35% of consolidated revenue in 2024 (22% and 13%).
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including insufficient segregation of duties and lack of systematic reconciliation procedures.
- Intangible Asset Valuation: Approximately $17.8 million of intangible assets are associated with Impact BioMedical. If licensing efforts fail, these assets may require further impairment.
Investor Verification Checklist
- Debt Resolution: Verify the status of negotiations with Pinnacle Bank regarding the defaulted LifeCare and Winter Haven loans ($49 million+).
- Asset Sales: Confirm the timeline and closing status of the sale of AMRE medical facilities (Plano, Fort Worth, Pittsburgh) classified as "held for sale."
- Going Concern: Assess the liquidity runway given the negative operating cash flow of $9.1 million and reliance on selling marketable securities or subsidiary shares.
- Internal Controls: Review the progress of remediation efforts for the identified material weaknesses in financial reporting.
- Revenue Quality: Analyze the sustainability of the Product Packaging segment, which remains the primary revenue generator, amidst customer concentration risks.